C. Karlsson

发表

Haralick texture features from apparent diffusion coefficient (ADC) MRI images depend on imaging and pre-processing parameters

Johan Trygg, Patrik Brynolfsson, Tufve Nyholm, 2017, Scientific Reports.

Quantifying the Effect of 3T Magnetic Resonance Imaging Residual System Distortions and Patient-Induced Susceptibility Distortions on Radiation Therapy Treatment Planning for Prostate Cancer.

Josef A. Lundman, J. Jonsson, T. Nyholm, 2018, International journal of radiation oncology, biology, physics.

Breast cancer as a second primary in patients with prostate cancer--estrogen treatment or association with family history of cancer?

H. Grönberg, F. Wiklund, B. Malmer, 2006, The Journal of urology.

Improved PET/MRI attenuation correction in the pelvic region using a statistical decomposition method on T2-weighted images

J. Axelsson, A. Larsson, J. Jonsson, 2020, EJNMMI Physics.

Risk Factors for Overall Survival Outcome in Surgically Treated Human Papillomavirus-Negative and Positive Patients with Oropharyngeal Cancer.

F. Saad, J. Carles, M. Wirth, 2017 .

11 C-Acetate-PET / CT Compared to 99 mTc-HDP Bone Scintigraphy in Primary Staging of High-risk Prostate Cancer

S. Strandberg, J. Axelsson, K. Riklund, 2016 .

The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease

P. Fransson, S. Carlsson, C. Karlsson, 2022, Scandinavian journal of urology.

Prostate Cancer Epidemiological studies of Risk Factors

C. Karlsson, 2008 .

11C-acetate PET/CT in pre-therapeutic lymph node staging in high-risk prostate cancer patients and its influence on disease management - a retrospective study

S. Strandberg, J. Axelsson, K. Riklund, 2014, EJNMMI Research.

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Thierry Gil, Camilla Thellenberg Karlsson, I. Tannock, 2013, The Lancet. Oncology.

Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC).

S. Severi, O. Sartor, P. Schwarzenberger, 2016, Clinical advances in hematology & oncology : H&O.

Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study

J. Eastham, P. Stattin, P. Nilsson, 2016, Scandinavian journal of urology.

Risk of Prostate Cancer after Trans Urethral Resection of BPH: A Cohort and Nested Case-Control Study

H. Grönberg, F. Wiklund, B. Melin, 2011, Cancers.

Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy

A. Bergh, Elin Thysell, A. Josefsson, 2022, Cancers.

Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE).

B. Tombal, V. Matveev, G. Gravis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases

S. Severi, Rui Li, O. Sartor, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.